Vial2Bag® Device Implementation Benefits Cost and Workflow

> “Implementation of a V2B system at our institution resulted in **substantial cost avoidance** when compared with outsourcing commercial RTU products or manufacturing sterile products.[1]”



Academic Medical Center

- Vial2Bag® Device Study: single center, retrospective analysis performed from June 2017 - July 2018
  - Annual Pharmacy Sterile Compounding: 150,000 patient-specific; 300,000 anticipatory

Cost Avoidance

$2,295,261

Annual cost avoidance realized from 250,000+ doses dispensed following Vial2Bag® device implementation

- Reduce pharmacy labor, equipment and material cost versus Locally Compounded Sterile Product (LCSP)
- Reduce risk of contamination and extend stability compared to LCSP
- Reduce expensive ready-to-use products
- Reduce anticipatory compounding waste[2]
- Allow for unused drugs to be returned to inventory[2]

Improved Workflow

41,082

Annual units of LCSP moved from pharmacy to point-of-care through ADS Vial2Bag® device dispensing

- Reduce time to first dose through preparation at point-of-care
- Utilize an Automated Dispensing System (ADS) to reduce medication errors related to preparation and administration of patient specific doses
- Increase medications stocked in ADS
- Flexible solution for managing drug shortages
- Universal compatibility with all manufacturers' 50, 100, and 250mL IV bags and 20mm vials

Optimizing drug product utilization can improve workflow and minimize cost

Supply Disruptions

97%

experience supply disruptions from their hospital’s manufacturer or outsourced facilities[3]

Safety Events

80%

experienced a patient safety event due to this supply disruption[3]

Resourcing Constraints

45%

agreed that outsourcing IV admixtures was cost-effective[3]

1 - Tran LK, Anger KE, Dell'Orfano H, Rocchio MA, Szumita PM. Evaluation of Cost, Workflow, and Safety of Implementing a Vial Transfer Device for Ready-to-Mix Drugs at an Academic Medical Center. J Pharm Pract. 2020 Jul 8:897190020938195. doi: 10.1177/0897190020938195. Epub ahead of print. PMID: 32638650.
2 - not included in cost avoidance calculation
3 - Gabay M, Hertig JB, Degnan D, Burger M, Yaniv A, Mclaughlin M, Lynn Moody M. Third Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems-2018. Am J Health Syst Pharm. 2020 Jan 24;77(3):215-220. doi: 10.1093/ajhp/zxz277. PMID: 31811297.

This study was conducted using a device that is no longer on the market. West now offers the Vial2Bag Advanced™ 20mm Admixture Device as its transfer device.